Article

Pall Corporation to Acquire ATMI's LifeSciences Business for $185 million

Pall Corporation, a solutions provider in filtration, separation and purification, has signed a definitive agreement with ATMI to acquire ATMI's LifeSciences business unit for $185 million.

Pall Corporation, a solutions provider in filtration, separation and purification, has signed a definitive agreement with ATMI to acquire ATMI’s LifeSciences business unit for $185 million. ATMI LifeSciences specializes in single-use bioprocess systems and consumables for the bio/pharmaceutical industry. According to the press release, the transaction is expected to close in Pall’s fiscal third quarter and will be subject to closing conditions, regulatory approvals and labor-related notifications.

Pall announced that for the balance of fiscal 2014, the company expects the acquisition to add $20 $30 million in revenue, be $0.05–$0.08 dilutive to EPS on a GAAP basis and almost breakeven on a cash EPS basis. Pall reaffirms its total overall fiscal 2014 guidance for pro forma EPS to be $3.30–$3.50.

Source: Pall Corporation

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related Videos
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
© 2025 MJH Life Sciences

All rights reserved.